

From: Liverpool-ECMC
Sent: 04 February 2020 09:15
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter February 2020 - Haematology

LIVERPOOL ECMC NEWSLETTER FEBRUARY 2020

HAEMATOLOGY



ASTRAZENECA JUNIOR INVESTIGATOR MEETING 20TH- 21ST MARCH 2020

AstraZeneca are hosting a Junior Investigator meeting on Friday 20th and Saturday 21st March 2020 in the Malmaison, Manchester.

This meeting is aimed at healthcare professionals who have a clear focus on oncology or immunology, and an interest in actively contributing to clinical and translational research in the UK.

The meeting will address a range of clinical research applications including cancer biology, screening, prevention and diagnosis, with the agenda made up of sessions that focus on the design and performance of oncology-related clinical research as well as methods of data and statistical analysis.

Please click [here](#) to download the agenda.

Information on how to register can be found [here](#).

OPEN RESEARCH WEEK EVENTS 10TH-14TH FEBRUARY 2020



How open practices can get you and your research noticed, published and cited - with Wiley Publishing

Elizabeth Gidney Room, Guild of Students' University of Liverpool, 3.00pm - 4:30pm, Wednesday 12th February 2020

An interactive workshop introducing Registered Reports, FAIRsharing and other open research practices lead by Kathryn Sharples (Senior Director for Open Access at Wiley). Introduced by Professor Bill Greenhalf (Liverpool ECMC)

Health and Open Data (responsible research and the ethics of sharing)

Sensor City, 3:30pm - 6:00pm, Thursday 13th February 2020

The event will be opened by Professor Iain Buchan, Programme Director for Digital Strategy and Partnerships Liverpool Heath Partners and will include talks from Dr Ivan Olier-Caparroso from LJMU and Mary Jane Monaghan from UoL. There will be a workshop organised by Open Data Manchester on Open Data and the challenges in implementing good practice.



NEW EARLY PHASE TRIALS OPENING SOON

PORT is for patients with mycosis fungoides or sezary syndrome who have relapsed / are refractory after at least 1 prior systemic therapy. It offers a combination of pembrolizumab and radiotherapy.

BI-1206 is for all patients with a CD32b+ B cell malignancy or CLL, who are relapsed/refractory to conventional treatments, or for whom no conventional

therapy exists, or has been declined by the patient.

It uses rituximab in combination with anti-CD32b for treatment over 4 weeks with maintenance over another year if the patient responds.

Please contact **Jane Tinsley** for potential referral to these trials.

OPEN TRIALS

Please contact **Jane Tinsley** for potential referral to these trials.

- Telephone: 0151 706 4886



- **HARMONY** – A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- **HERACLES** – Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase after Allogeneic hematopoietic stem cell transplantation with faecal microbiota transfer
- **MANIFEST** – A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
- **TIDaL** – Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

Find out more...

EVENTS & JOB OPPORTUNITIES

EVENTS

- **Open Research Week Events (10TH-14TH FEBRUARY 2020)**
- **AstraZeneca Junior Investigator Meeting (20TH-21ST MARCH 2020)**

- <https://www.ecmcnetwork.org.uk/events>

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via **e-mail**.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk